NxStage Medical, Inc. (NXTM) Expected to Post Earnings of -$0.02 Per Share

Share on StockTwits

Analysts expect NxStage Medical, Inc. (NASDAQ:NXTM) to post earnings of ($0.02) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for NxStage Medical’s earnings. The highest EPS estimate is $0.02 and the lowest is ($0.05). NxStage Medical posted earnings of ($0.14) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 85.7%. The firm is expected to announce its next quarterly earnings report on Wednesday, November 14th.

On average, analysts expect that NxStage Medical will report full-year earnings of ($0.02) per share for the current financial year, with EPS estimates ranging from ($0.15) to $0.13. For the next fiscal year, analysts forecast that the business will post earnings of $0.09 per share, with EPS estimates ranging from ($0.05) to $0.25. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for NxStage Medical.

NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings data on Tuesday, August 7th. The medical device company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $106.97 million for the quarter, compared to analyst estimates of $105.35 million. NxStage Medical had a negative net margin of 3.67% and a negative return on equity of 7.02%.

NXTM has been the topic of several analyst reports. Zacks Investment Research lowered shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Saturday, August 11th. BidaskClub lowered shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Monday, September 17th. Finally, ValuEngine upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. NxStage Medical presently has an average rating of “Hold” and a consensus target price of $30.00.

NXTM stock traded up $0.21 during midday trading on Wednesday, hitting $28.20. 11,026 shares of the stock traded hands, compared to its average volume of 486,566. The firm has a market cap of $1.83 billion, a PE ratio of -126.64 and a beta of -0.06. NxStage Medical has a 1-year low of $22.70 and a 1-year high of $28.75.

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in NxStage Medical by 10.5% during the second quarter. BlackRock Inc. now owns 5,289,606 shares of the medical device company’s stock valued at $147,581,000 after purchasing an additional 501,922 shares in the last quarter. Alpine Associates Management Inc. lifted its holdings in NxStage Medical by 0.9% during the second quarter. Alpine Associates Management Inc. now owns 3,326,982 shares of the medical device company’s stock valued at $93,087,000 after purchasing an additional 30,300 shares in the last quarter. Water Island Capital LLC lifted its holdings in NxStage Medical by 12.6% during the second quarter. Water Island Capital LLC now owns 1,334,420 shares of the medical device company’s stock valued at $37,230,000 after purchasing an additional 149,713 shares in the last quarter. Northern Trust Corp lifted its holdings in NxStage Medical by 3.0% during the second quarter. Northern Trust Corp now owns 885,227 shares of the medical device company’s stock valued at $24,697,000 after purchasing an additional 25,633 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in NxStage Medical by 5.2% during the second quarter. Bank of New York Mellon Corp now owns 605,270 shares of the medical device company’s stock valued at $16,888,000 after purchasing an additional 29,934 shares in the last quarter. Institutional investors own 83.12% of the company’s stock.

About NxStage Medical

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Read More: Tariff

Get a free copy of the Zacks research report on NxStage Medical (NXTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply